Imatinib is under clinical development by Aerami Therapeutics and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase I drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Imatinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imatinib overview
Imatinib (AER-901) is under development for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD) . It is administered through inhalation route. It acts by targeting Bcr-Abl tyrosine kinase, platelet derived growth factor receptor and mast/stem cell growth factor receptor kit.
Aerami Therapeutics overview
Aerami Therapeutics (Aerami), formerly Aerami Therapeutics Inc, is a biotechnology company that develops inhaled insulin products to treat diabetes patients. The company provides a product pipeline such as AER-901 – Inhaled Imatinib, AER-601 – Soft-mist Inhaled Exenatide and AER-501 – Soft-mist Inhaled Insulin among others. It has completed Phase II clinical trials and is in preparation for pivotal development. Aerami offers AER-501 designed to control prandial blood sugar in adults with diabetes without the need for injections. The company develops liquid formulations of insulin based on the vibrating mesh micropump technology developed and commercialized by Aerogen. Aerami is headquartered in Durham, North Carolina, US.
For a complete picture of Imatinib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
